LONDON, Feb 10 (Reuters) - Shire (SHP.L) posted earnings in line with market expectations, helped by its hyperactivity drug Vyvanse and the windfall it is continuing to reap in rare diseases from production problems at rival Genzyme (GENZ.O).
LONDON, Feb 10 (Reuters) - Shire (SHP.L) posted earnings in line with market expectations, helped by its hyperactivity drug Vyvanse and the windfall it is continuing to reap in rare diseases from production problems at rival Genzyme (GENZ.O).